MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-08-2022
ChemoCentryx Operating Expenses 2011-2026 | CCXI
Annual Operating Expenses ChemoCentryx
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 120 M | 94.3 M | 83.1 M | 66 M | 52.2 M | 47.7 M | 47.4 M | 45.2 M | 45 M | 36 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 120 M | 36 M | 63.7 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ADMA Biologics
ADMA
|
101 M | $ 16.34 | -0.24 % | $ 3.89 B |  USA |
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Axsome Therapeutics
AXSM
|
99.1 M | $ 165.22 | 0.71 % | $ 8.22 B | USA |
 |
Graybug Vision
GRAY
|
23.1 M | - | -11.23 % | $ 9.65 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
948 M | $ 19.73 | -2.13 % | $ 2.49 B | USA |
 |
Aptorum Group Limited
APM
|
20.7 M | $ 0.8 | 1.02 % | $ 4.36 M |  China |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
 |
BioLineRx Ltd.
BLRX
|
28.1 M | $ 2.85 | 1.25 % | $ 908 M |  Israel |
 |
AbCellera Biologics
ABCL
|
292 M | $ 3.71 | -0.13 % | $ 1.11 B |  Canada |
 |
Athersys
ATHX
|
79.8 M | - | 3.77 % | $ 22.4 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
44.9 M | - | - | $ 521 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
1.47 B | $ 59.28 | 1.28 % | $ 11.4 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | USA |
 |
Burford Capital Limited
BUR
|
106 M | $ 8.56 | 0.12 % | $ 1.38 B | Britain |
 |
Capricor Therapeutics
CAPR
|
49.3 M | $ 26.06 | 0.77 % | $ 698 M | USA |
 |
BridgeBio Pharma
BBIO
|
304 M | $ 65.0 | 0.73 % | $ 12.4 B | USA |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
CymaBay Therapeutics
CBAY
|
133 M | - | - | $ 3.45 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
26 M | - | - | $ 789 M | USA |
 |
Codexis
CDXS
|
31.5 M | $ 1.0 | 2.04 % | $ 73.4 M | USA |
 |
Certara
CERT
|
237 M | $ 7.43 | 2.56 % | $ 1.19 B | USA |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
56.2 M | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
23.4 M | - | -16.75 % | $ 25.8 M | USA |
 |
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | USA |
 |
Clovis Oncology
CLVS
|
425 M | - | -7.23 % | $ 13 M | USA |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
61.5 M | - | - | $ 231 M | USA |
 |
Coherus BioSciences
CHRS
|
231 M | $ 1.77 | 7.27 % | $ 167 M | USA |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | Canada |
 |
CTI BioPharma Corp.
CTIC
|
47.8 M | - | - | $ 1.2 B | USA |
 |
CohBar
CWBR
|
12.4 M | - | -15.44 % | $ 2.2 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
12 M | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
12 M | - | -4.36 % | $ 27 M | USA |
 |
Cabaletta Bio
CABA
|
74.7 M | $ 3.36 | 3.23 % | $ 3.92 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
226 M | - | - | $ 2.18 B | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M | Canada |
 |
CorMedix
CRMD
|
49 M | $ 7.09 | 2.53 % | $ 361 M | USA |
 |
Corvus Pharmaceuticals
CRVS
|
23.4 M | $ 17.3 | -1.31 % | $ 831 M | USA |
 |
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |